• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    2/19/25 4:30:16 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care
    Get the next $HLF alert in real time by email
    false 0001180262 0001180262 2025-02-13 2025-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): February 13, 2025

     

     

     

    Herbalife Ltd.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Cayman Islands   1-32381   98-0377871

    (State or Other Jurisdiction
    of Incorporation)

     

    (Commission File Number)

     

     

    (IRS Employer
    Identification No.)

       

    P.O. Box 309, Ugland House,

    Grand Cayman

    Cayman Islands

      KY1-1104
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: c/o (213) 745-0500

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange

    on which registered

    Common Shares, par value $0.0005 per share   HLF   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On February 19, 2025, Herbalife Ltd. (the “Company”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

     

    The information contained in this Item 2.02 and Exhibit 99.1 attached to this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Leadership Succession

     

    On February 13, 2025, Stephan Paulo Gratziani, the Company’s current President, was appointed as the Company’s Chief Executive Officer, effective May 1, 2025 (the “Effective Date”), succeeding Michael O. Johnson, the Company’s current Chairman and Chief Executive Officer, who will concurrently transition to serve as the Company’s Executive Chairman. As of the Effective Date, Rob Levy, the Company’s current Managing Director, International, will succeed Mr. Gratziani to serve as the Company’s President – Worldwide Markets.

     

    Notwithstanding anything in his employment agreement to the contrary, in connection with his role as Executive Chairman, beginning on the Effective Date, Mr. Johnson will have an annual salary of $740,741 and a target annual cash incentive equal to 125% of base salary (with a maximum annual cash incentive of 200% of target), subject to actual performance. In addition, Mr. Johnson will continue to be eligible for an equity incentive award in 2025 having a grant date fair value equal to $8,000,000 of which $2,666,666 is in connection with 4 months of service as Chief Executive Officer beginning from January 1, 2025 plus $5,333,334 for 12 months of service from the Effective Date as Executive Chairman (the “Johnson Equity Awards”). The Johnson Equity Awards will consist of the following: (i) 50% of the value of the Johnson Equity Awards will be granted in the form of Performance Stock Units that are subject performance-based vesting criteria (“PSUs”), (ii) 25% of the value of the Johnson Equity Awards will be granted in the form of restricted cash units (“RCUs”) and (iii) 25% of the value of the Johnson Equity Awards will be granted in the form of Stock Appreciation Rights (“SARs”). Mr. Johnson shall also continue to be entitled to personal use of private aircraft paid by the Company, subject to an annualized limit of $500,000 based on the incremental cost to the Company of such use.

     

    The Johnson Equity Awards will vest, subject to continued service through the applicable vesting date as an employee and/or member of the Board of Directors of the Company (the “Board”), in two installments, 50% on the first anniversary of the date on which they are granted (the “Grant Date”), and 50% on the date of the Company’s Annual General Meeting of Shareholders in 2026. The SARs that are granted as part of the Johnson Equity Awards will remain outstanding for the full ten-year term unless Mr. Johnson’s employment is terminated for “cause” (as defined in the applicable award agreement). The PSU performance metrics will be the same as those for the Company’s Executive Vice Presidents, except that the vesting of the PSUs will be subject to achievement of cumulative goals set for fiscal years 2025 and 2026. Notwithstanding the foregoing, if (i) Mr. Johnson voluntarily resigns as Chief Executive Officer or Executive Chairman, as applicable, prior to the date of the Company’s Annual General Meeting of Shareholders in 2026, any unvested portion of the Johnson Equity Awards will be forfeited; (ii) Mr. Johnson is terminated as Chief Executive Officer or Executive Chairman, as applicable, without “cause” (as defined in the applicable award agreement) or is not re-elected or nominated by the Company for election to the Board, then, subject to his execution and non-revocation of a general release of claims in favor of the Company, the Johnson Equity Awards shall accelerate based on the number of days Mr. Johnson was providing continuous service as an employee and/or member of the Board during the vesting period and, for any PSUs, the Company’s achievement with respect to the applicable performance metric(s); or (iii) Mr. Johnson is involuntarily terminated from his position as Chief Executive Officer or Executive Chairman, as applicable, within twenty-four (24) months following a “change in control” (as defined in the Plan), the Johnson Equity Awards will be subject to acceleration as provided in Section 15(c) of the Company’s Amended and Restated 2023 Stock Incentive Plan, as amended from time to time. Mr. Johnson will continue to be ineligible to participate in the Herbalife International of America, Inc. Executive Officer Severance Plan.

     

    1

     

     

    In connection with his role as Chief Executive Officer, beginning on the Effective Date, Mr. Gratziani will have an annual salary of $1,100,000, and a target annual cash incentive equal to 150% of base salary (with a maximum annual cash incentive of 200% of target), subject to actual performance. In addition, Mr. Gratziani will be eligible for a prorated equity incentive award for 2025 having a grant date fair value equal to $5,600,000 (the “Gratziani Equity Awards”). The Gratziani Equity Awards will consist of the following: (i) 50% of the value of the Gratziani Equity Awards will be granted in the form of PSUs, (ii) 25% of the value of the Gratziani Equity Awards will be granted in the form of RCUs and (iii) 25% of the value of the Gratziani Equity Awards will be granted in the form of SARs. The portions of the Gratziani Equity Awards granted in the form of SARs and RCUs will vest, subject to continued employment with the Company, in equal annual installments over three years from the date of grant. The portion of the Gratziani Equity Awards granted in the form of PSUs will vest based on continued employment and the satisfaction of the performance-based vesting criteria on the third anniversary of the date of grant.

     

    Mr. Gratziani, 56, has served as the Company’s President since January 2024. Mr. Gratziani previously served as the Company’s Chief Strategy Officer from August 2023 to January 2024. Mr. Gratziani also served on the Company’s Board from April 2023 to August 2023. Prior to becoming an employee of the Company, Mr. Gratziani served as an independent Herbalife distributor for 32 years. In connection with his prior service as Chief Strategy Officer and as consideration for suspending the operation of his distributorship under the Company’s marketing plan upon accepting such position, Mr. Gratziani received $1,000,000 since January 1, 2024 pursuant to the arrangement described in the 2023 Director Compensation Table in the Company’s definitive proxy statement for the Company’s 2024 General Annual Meeting of Shareholders.

     

    In connection with his role as President, Mr. Levy will have an annual salary of $640,000 and a target annual cash incentive equal to 80% of base salary (with a maximum annual cash incentive of 200% of target), subject to actual performance. In addition, Mr. Levy will be eligible for a prorated equity incentive award for 2025 having a grant date fair value equal to $933,333 (the “Levy Equity Awards”). The Levy Equity Awards will consist of the following: (i) 50% of the value of the Levy Equity Awards will be granted in the form of PSUs, (ii) 25% of the value of the Levy Equity Awards will be granted in the form of RCUs and (iii) 25% of the value of the Levy Equity Awards will be granted in the form of SARs. The portions of the Levy Equity Awards granted in the form of SARs and RCUs will vest, subject to continued employment with the Company, in equal annual installments over three years from the date of grant. The portion of the Levy Equity Awards granted in the form of PSUs will vest based on continued employment and the satisfaction of the performance-based vesting criteria on the third anniversary of the date of grant.

     

    Mr. Levy, 66, has served as Managing Director, International, since May 2024. Prior his role as Managing Director, International, Mr. Levy served as Regional President of the Americas from July 2023 to May 2024, Executive Vice President, Worldwide Distributor Relations from August 2022 to June 2023, and Executive Vice President, Worldwide Distributor Affairs & Latin America from December 2019 to August 2022. From May 2018 until December 2019, Mr. Levy was the Executive Vice President of the Americas and Worldwide Distributor Affairs, from August 2017 to May 2018, the Executive Vice President of the Americas, and from December 2013 to August 2017, the Executive Vice President of APAC, China, EMEA and Worldwide Sales and Marketing. Prior to such roles, Mr. Levy held successive roles and responsibilities at the Company over various operations, sales and distributor-facing functions around the globe, having joined the Company in November 1994. Mr. Levy holds a Bachelor of Arts degree in economics from Boston University.

     

    Item 7.01. Regulation FD Disclosure.

     

    A copy of the press release announcing the leadership succession is attached hereto as Exhibit 99.2 and incorporated herein by reference.

     

    The Company intends to reference investor slides during the Company’s earnings conference call to discuss its financial results for its fourth fiscal quarter and fiscal year ended December 31, 2024. A copy of the presentation can be accessed in the “News and Events” section on the investor relations section of the Company’s website at http://ir.herbalife.com under the heading “IR Calendar”.

     

    The information included in this Item 7.01 and exhibit 99.2 attached to this report shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    99.1 Press Release by Herbalife announcing fourth fiscal quarter and fiscal year ended December 31, 2024 financial results, dated February 19, 2025

    99.2 Press Release by Herbalife announcing leadership succession, dated February 19, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Herbalife Ltd.
         
    February 19, 2025 By:

    /s/ HENRY C. WANG

        Name:  Henry C. Wang
        Title: Chief Legal Officer and Corporate Secretary

     

     

    3

     

    Get the next $HLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLF

    DatePrice TargetRatingAnalyst
    3/21/2025$7.50 → $14.00Neutral → Buy
    DA Davidson
    8/1/2024$16.00 → $17.00Buy
    B. Riley Securities
    9/14/2023$13.50Neutral
    DA Davidson
    6/7/2023$13.00Neutral
    Mizuho
    2/3/2023$14.00Underperform
    BofA Securities
    7/12/2022$26.00Hold → Buy
    Jefferies
    5/17/2022Buy → Hold
    Argus
    5/4/2022$60.00 → $26.00Buy → Hold
    Jefferies
    More analyst ratings

    $HLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL

      Certified Method Enhances Global Botanical Quality and Safety Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)—a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-app

      6/11/25 7:14:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife to Participate in MicroCap Rodeo Conference on June 4

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced John DeSimone, Chief Financial Officer, will participate in a fireside chat at the MicroCap Rodeo Conference on Wednesday, June 4, 2025 at 9:30 a.m. ET (6:30 a.m. PT). The webcast will be available at the following link: https://www.webcaster4.com/Webcast/Page/3119/52530 The webcast will also be available under the Investor Relations section of Herbalife's website at https://ir.herbalife.com/. A replay of the webcast will be available at the same website following the completion of the event and for six months thereafter. For more details about the MicroCap Rodeo Conference in New

      5/27/25 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Reports Q1 Net Sales at Midpoint of Guidance Range, Net Sales Growth Excluding FX Headwinds1; Q1 Adjusted EBITDA2 Exceeds Guidance; Updates Full-Year Guidance

      Herbalife Ltd. (NYSE:HLF) today reported financial results for the first quarter ended March 31, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430667438/en/ "Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth," Stephan Gratziani, President and incoming CEO (effective May 1 '25). Highlights First Quarter 2025 Net sales of $1.2 billion at midpoint of guidance range Down 3.4% vs. Q1 ‘24 Includes 480 basis points of FX headwinds Up 1.4% year-over-year on constant cu

      4/30/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Herbalife Nutrition upgraded by DA Davidson with a new price target

      DA Davidson upgraded Herbalife Nutrition from Neutral to Buy and set a new price target of $14.00 from $7.50 previously

      3/21/25 8:38:07 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • B. Riley Securities reiterated coverage on Herbalife Nutrition with a new price target

      B. Riley Securities reiterated coverage of Herbalife Nutrition with a rating of Buy and set a new price target of $17.00 from $16.00 previously

      8/1/24 8:12:23 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • DA Davidson initiated coverage on Herbalife Nutrition with a new price target

      DA Davidson initiated coverage of Herbalife Nutrition with a rating of Neutral and set a new price target of $13.50

      9/14/23 7:19:53 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      6/9/25 6:00:12 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/23/25 4:01:25 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • New insider Levy Robert claimed ownership of 449,358 shares (SEC Form 3)

      3 - HERBALIFE LTD. (0001180262) (Issuer)

      5/12/25 7:39:33 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care

    $HLF
    SEC Filings

    See more

    $HLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HLF
    Leadership Updates

    Live Leadership Updates

    See more

    $HLF
    Financials

    Live finance-specific insights

    See more

    $HLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HERBALIFE LTD. (0001180262) (Filer)

      4/30/25 4:40:01 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Herbalife Ltd.

      10-Q - HERBALIFE LTD. (0001180262) (Filer)

      4/30/25 4:16:43 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Herbalife Ltd.

      SCHEDULE 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      4/30/25 11:12:30 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      6/9/25 6:00:12 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/23/25 4:01:25 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Director Mendoza Juan Miguel bought $33,650 worth of shares (5,000 units at $6.73) and was granted 21,857 shares, increasing direct ownership by 20% to 161,857 units (SEC Form 4)

      4 - HERBALIFE LTD. (0001180262) (Issuer)

      5/6/25 8:19:33 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Welcomes Lynda Cloud to its Board of Directors

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the election of Lynda Cloud to its Board of Directors, effective April 23, 2025. This appointment reflects Herbalife's continued commitment to innovation, digital transformation, and personalized wellness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425107883/en/Herbalife Welcomes Lynda Cloud to the Board of Directors Lynda Cloud's decades of leadership across education, technology, and health sectors make her uniquely equipped to support Herbalife's next chapter. Her deep expertise in digital learning, consumer experie

      4/25/25 5:12:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Appoints Stephan Gratziani as Chief Executive Officer

      Current CEO Michael Johnson Transitions to Executive Chairman Herbalife Ltd. (NYSE:HLF) today announced its Board of Directors has appointed President, Stephan Gratziani as Chief Executive Officer (CEO) effective May 1, 2025. Michael Johnson, current CEO and Chairman of the Board, will transition to Executive Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219653469/en/Herbalife appoints Stephan Gratziani as Chief Executive Officer (Photo: Business Wire) As a former Herbalife independent distributor, Mr. Gratziani built and grew his international business into one of the top global distributorships. For 32 years, he

      2/19/25 4:05:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Expands Board of Directors with Appointment of Perkins Miller

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today welcomed experienced e-commerce and media technology executive Perkins Miller to its board of directors. Miller's appointment as an independent director is effective June 26, 2024. "Perkins brings valuable, proven expertise in leading large-scale e-commerce, technology and sports enterprises, which will be a great asset to our Board as the Company continues to grow and transform," said Michael Johnson, Chairman and CEO of Herbalife. Miller is the CEO of Fandom, the world's largest fan platform where fans immerse themselves in imagined worlds across entertainment and gaming, where he has trans

      6/26/24 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Reports Q1 Net Sales at Midpoint of Guidance Range, Net Sales Growth Excluding FX Headwinds1; Q1 Adjusted EBITDA2 Exceeds Guidance; Updates Full-Year Guidance

      Herbalife Ltd. (NYSE:HLF) today reported financial results for the first quarter ended March 31, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430667438/en/ "Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth," Stephan Gratziani, President and incoming CEO (effective May 1 '25). Highlights First Quarter 2025 Net sales of $1.2 billion at midpoint of guidance range Down 3.4% vs. Q1 ‘24 Includes 480 basis points of FX headwinds Up 1.4% year-over-year on constant cu

      4/30/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife to Announce First Quarter 2025 Results on April 30

      Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, will release its first quarter 2025 financial results after the close of trading on the NYSE on Wednesday, April 30, 2025. On the same day, at 5:30 p.m. ET (2:30 p.m. PT), Herbalife's senior management team will host an audio webcast and conference call to discuss its recent financial results. The audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/bd8j8th6 Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link: https://register-conf.media-server.com/register/BI1210

      4/1/25 7:05:00 AM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Herbalife Reports Q4 Net Sales at High End of Guidance, Q4 and Full-Year Net Sales Growth Excluding FX Headwinds1; Q4 Adjusted EBITDA2 Exceeds Guidance

      Stephan Gratziani Appointed CEO; Michael Johnson Named Executive Chairman Herbalife Ltd. (NYSE:HLF) today reported financial results for the fourth quarter and year ended December 31, 2024: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219267078/en/ "With three consecutive quarters of new distributor growth, a new incoming CEO and significantly improved Adjusted EBITDA2 margins, we enter 2025 with strong momentum." - Michael Johnson, Chairman and CEO Highlights Fourth Quarter 2024 Net sales of $1.2 billion, down 0.6% vs. Q4 '23 and at high end of guidance range Includes 330 basis points of FX headwinds Up 2.7% year-o

      2/19/25 4:10:00 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

      SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      11/14/24 4:11:11 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Herbalife Ltd.

      SC 13G - HERBALIFE LTD. (0001180262) (Subject)

      11/13/24 4:01:31 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

      SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

      11/13/24 12:49:27 PM ET
      $HLF
      Other Pharmaceuticals
      Health Care